BJ
Therapeutic Areas
Immunocore Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KIMMTRAK (tebentafusp) | HLA-A*02:01-positive metastatic uveal melanoma | Approved |
| IMC-F106C (PRAME ImmTAC) | HLA-A*02:01+ advanced cutaneous melanoma (1L combo) | Phase 3 |
| IMC-F106C | HLA-A*02:01+ non-small cell lung cancer (NSCLC) | Phase 2 |
| IMC-M113V (HBV ImmTAV) | Chronic Hepatitis B Virus (HBV) infection | Phase 1 |
| IMC-I109V (HIV ImmTAV) | Human Immunodeficiency Virus (HIV) infection | Phase 1 |